Zunarelli Studio Legale Associato launches its initiative ZUNARELLI ACADEMY, to share events, contributions and scientific publications on legal and business topics related both to Chinese and EU-Italian jurisdiction, organized by our Firm, or hosted by scientific institutions, business organizations or legal magazines, with our lawyers as speakers or authors.
The new logo of ZUNARELLI ACADEMY is an homage to the ancient traditions both of Roman law and Confucian teachings, pillars of the law history along the Silk Road.
Today, ZUNARELLI ACADEMY presents two contributions of our Professionals respectively on Corporate Governance and Pricing & Reimbursement. Published within ICLG Global Legal Insights comparative guides, our Firm is exclusive contributor for Italy Chapter – Corporate Governance, and for China Chapter – Pricing & Reimbursement.
Corporate Governance – Italy Chapter 2021 – by Luigi Zunarelli and Lorenzo Ferruzzi
The attention of Italian policy makers as well as that of business operators is currently focused on the following aspects: (i) the growing importance of ESG (environmental, social and governance) factors in the management of the corporations, (ii) gender diversity and gender equality in boards of directors and supervisory boards, (iii) the directors’ remuneration policy, (iv) the strengthening of dialogue between the board of directors and the shareholders and other relevant stakeholders (v) the encouragement of long-term shareholder engagement, (vi) the strengthening in the management of the insider trading.
Despite the topicality of these issues, both nationally and at European level, almost all of them apply only to listed SPAs and many of them are regulated only in soft law (most recently in the Corporate Governance Code). No mandatory provisions have yet been approved and implemented. Starting from 2022, Italian listed companies that have adopted the Corporate Governance Code will have to disclose, through their reporting on corporate governance and ownership structures, the measures adopted, and the extent of implementation of the new principles and recommendations established by the Code.
To see the whole contribution, please click on the link below:
Corporate Governance 2021 | Laws and Regulations | Italy | ICLG
Pricing & Reimbursement – China Chapter 2021 – by Andrea Sorgato
The complexity of pricing and reimbursement regulations is a key indicator of the evolution rate of a pharmaceutical law system. In recent years, China is facing the challenge to make its Healthcare system modern, inclusive, and able to cover the healthcare needs of Chinese citizens. The Pharmaceutical system – and the pharma pricing and reimbursement sub-system – is a key component of this process. The reform put in place by the Chinese Government involves deep changes in the Healthcare system, which have an impact on the whole life of drugs, from pre-clinical investigation activities to the commercial phase. Price setting and reimbursement procedures and areas of requirements are facing continuous reforms to conjugate huge healthcare coverage with sustainability of public insurance funds. Pharmaceutical companies must deeply know these changes. Being frequently updated is mandatory. The introduction of the revision of the National Drug Reimbursement List on a yearly basis, together with the VPB Volume-Based Procurement system to put in concurrence originators with generics (regardless of drugs domestic-made or imported) on a national-centralised scale, significantly infers drugs’ life from its early stage, included price setting and market access strategies for negotiation of reimbursement.
To see the whole contribution, please click the link below:
Pricing & Reimbursement Laws and Regulations | China | GLI (globallegalinsights.com)
